Skip to main content
Home
 
 
 
MENU
Home
Janssen’s COVID-19 Vaccine Status >

Janssen Global Main Menu

  • Our Company
    • About Us
    • Contact Us
    • Grants & Giving
    • News Center
    • Our Leaders
    • Patient Safety information
    • Products
    • Sustainability
    • Transparency
    • VISIT JANSSEN IN YOUR COUNTRY
  • Our Focus
    • Therapeutic Areas
    • Cardiovascular, Metabolism and Retina
    • Immunology
    • Infectious Diseases & Vaccines
    • Neuroscience
    • Oncology
    • Pulmonary Hypertension
    • Patient Engagement
  • Our Science
    • Our Response to COVID-19
    • Clinical Trials
    • Compassionate Use & Pre-Approval Access
    • R&D Data Science
    • Janssen Global Trial Finder
    • World Without Disease Accelerator
    • Janssen Clinical Innovation
    • Precision Medicine & Janssen Diagnostics

Our Stories List

Making a Splash for Disease Awareness
Global_Trial_Finder
Making a Splash for Disease Awareness
Looking Under the Hood for Green Chemistry Solutions
Global_Trial_Finder
Looking Under the Hood for Green Chemistry Solutions
  • Return to home

Global Trial Finder

  • text size

My Saved Trials

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants (TRILOGY)

Last Updated   April 17, 2025

Want to learn how to participate in this trial?

CNTO1959ISD3001

OVERVIEW

  • Sexes Eligible for Study
    all
  • Age
    3+ years
  • Phase
    phase 3
    3
  • Sites
    3 Sites
  • Status
    Recruiting

SUMMARY

The purpose of this study is to evaluate long-term safety of subcutaneous guselkumab in pediatric participants with moderately to severely active ulcerative colitis, or moderately to severely active Crohn's disease, or juvenile psoriatic arthritis (jPsA).

CONDITIONS

  • Crohn's Disease
  • Colitis, Ulcerative
  • Arthritis, Psoriatic
  • Arthritis, Juvenile

ELIGIBILITY


Inclusion Criteria:

* Must have completed the dosing planned in the primary pediatric guselkumab study
* Must have received benefit from continued guselkumab therapy in the opinion of the investigator
* Before enrollment, a participant must be either: (a) Not of childbearing potential, OR (b) Of childbearing potential and not sexually active, practicing abstinence or a highly effective method of contraception and agrees to remain on a highly effective method while receiving study intervention and until 12 weeks after the last dose - the end of relevant systemic exposure
* Parent(s) (or their legally acceptable representative) must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to allow the child to participate in the study. Assent is required from participants who are capable of understanding the nature of the study, typically those aged 7 years and older, to ensure their willingness to participate. An adolescent who provides assent will have the opportunity to sign an adult ICF upon reaching the age of majority, thereby affirming their understanding of the study's purpose and procedures, as well as their willingness to participate.


Exclusion Criteria:

* Participant is greater than or equal to (>=) 18 years of age and resides in a country where 2 years have elapsed post marketing authorization for the respective adult indication
* Participant is <18 years of age and resides in a county where 2 years have elapsed post marketing authorization for the respective pediatric indication
* Are pregnant, nursing, or planning pregnancy or fathering a child
* Have taken any disallowed therapies before the planned first long-term extension (LTE) dose of study intervention
* Employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, as well as family members of the employees or the investigator
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participant or that could prevent, limit, or confound the protocol-specified assessments


Inclusion Criteria:

* Must have completed the dosing planned in the primary pediatric guselkumab study
* Must have received benefit from continued guselkumab therapy in the opinion of the investigator
* Before enrollment, a participant must be either: (a) Not of childbearing p

More...

DETAILS

LOCATIONS

Locations in:
Spain, United States, China
Country (3) City or Province (3) Status
Spain Santiago de Compostela Hosp. Clinico Univ. de Santiago
RECRUITING
United States Salt Lake City University of Utah
RECRUITING
China Changzhou Changzhou No 2 Peoples Hospital
RECRUITING
Show More
Geo Locations

42.88052, -8.54569

40.76078, -111.89105

31.77359, 119.95401

x
50

Indicates 50+ sites in this region: click to zoom in.

10

Indicates 10+ sites in this region: click to zoom in.

5

Indicates < 10 sites in this region: click to zoom in.

Corresponds to individual site.

Interested in participating?

×

Confirm


If you are interested in this clinical trial, we will use your email address to respond to your questions and fulfill your requests as necessary for our legitimate interest and possibly to comply with our legal obligations relating to pharmacovigilance. Please read our Privacy Policy.

Footer

  • PRIVACY POLICY
  • LEGAL NOTICE
  • COOKIE POLICY
  • COOKIE SETTINGS
  • CAREERS
  • NEWS CENTER
  • DO NOT SELL MY PERSONAL INFORMATION

Footer Social

Find Janssen Global on:

twitter youtube linkedin

Janssen Global Policy text

©Johnson & Johnson Innovative Medicine. All Rights Reserved. This website is hosted and operated by Johnson & Johnson Innovative Medicine, which is solely responsible for its content. This website is intended for a global audience.